



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): BURTON et al. Group Art Unit: 1714
Serial No.: 10/728,439 Examiner: Vickey M. Ronesi
Confirmation No.: 9418 Filed: 5 December 2003 Docket No.: 59405US002
Title: POLYMER COMPOSITIONS WITH BIOACTIVE AGENT, MEDICAL ARTICLES, AND METHODS

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

We are transmitting the following documents along with this Transmittal Sheet (which is submitted in triplicate):

An itemized return postcard.
 A Petition for Extension of Time for month(s). Please charge Deposit Account No. 13-4895 in the amount of \$ for the required fee.
 An Information Disclosure Statement (2 pgs); copies of 0 applications; 1449 form (3 pgs); and copies of 20 documents cited on the 1449 form.
 A request for continued examination (RCE). Please charge Deposit Account No. 13-4895 in the amount of \$810, for the required filing fee.
 An Appeal Brief. Please charge Deposit Account No. 13-4895 in the amount of \$510, for the required Appeal Brief filing fee.
 Please charge Deposit Account No. 13-4895 in the amount of \$180.00 for the IDS fee.
 A certified copy of a application, Serial No. , filed , the right of priority of which is claimed under 35 U.S.C. §119.
 Other:
Amendment No Additional fee is required. The fee has been calculated as shown:

Fee Calculation for Claims Pending After Amendment					
	Pending Claims after Amendment (1)	Claims Paid for Earlier (2)	Number of Additional Claims (1-2)	Cost per Additional Claim	Additional Fees Required
Total Claims				x \$50 =	
Independent Claims				x \$210 =	
One or More New Multiple Dependent Claims Presented? If Yes, Add \$370 Here →					
Total Additional Claim Fees Required					

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 13-4895. Triplicate copies of this sheet are enclosed.

CERTIFICATE UNDER 37 C.F.R. §1.8: The undersigned hereby certifies that this Transmittal Letter and the paper(s), as described hereinabove, are being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: **Mail Stop Amendment**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-

Void 11/05/2007 MBLANCO of October 2007
11/05/2007 MBLANCO 00000003 134895 10728439
01 MUETING, RAASCH & GEBHARDT, P.A.

By: Ann M. Muetting

Ann M. Muetting

Reg. No.: 33,977

Direct Dial: 612-305-1217

Facsimile: 612-305-1228

11/05/2007 MBLANCO 00000003 134895 10728439
01 FC:1801 810.00 DA

(LARGE ENTITY TRANSMITTAL UNDER RULE 1.8)



PATENT
Docket No. 59405US002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): BURTON et al.) Group Art Unit: 1714
Serial No.: 10/728,439)
Confirmation No.: 9418) Examiner: Vickey M. Ronesi
Filed: 5 December 2003)
For: POLYMER COMPOSITIONS WITH BIOACTIVE AGENT, MEDICAL
ARTICLES, AND METHODS

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

11/05/2007 MBLANCO 00000026 134895 10728439
01 FC:1886 180.00 DA

Dear Sir:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with C.F.R. §§ 1.97 *et. seq.*, the materials enclosed herewith are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application. Pursuant to MPEP § 609, the information cited in the present Information Disclosure Statement shall not be construed to be an admission that the information is, or is considered to be, material to patentability. Consideration of each of the documents listed on the attached 1449 form is respectfully requested. Pursuant to the provisions of M.P.E.P. §609, Applicants further request that a copy of the 1449 form, marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

Applicants also wish to bring the Examiner's attention to any issued U.S. Patents and/or pending U.S. Applications cited in the 1449 form submitted herewith, as well as any documents, Office Actions that may include rejections of similar claims, and any provisional U.S. patent applications referenced in the pending U.S. applications or in their file wrappers.

Copies of U.S. Patent and Applications 11/550,440 and 11/550,434, which are available on the
11/05/2007 MBLANCO 00000023 134895 10728439
U.S.P.T.O. Image File Wrapper (IFW) System are not provided herewith.
01 FC:1886 180.00 DA

Information Disclosure Statement

Page 2 of 2

Serial No.: 10/728,439

Confirmation No.: 9418

Filed: 5 December 2003

For: POLYMER COMPOSITIONS WITH BIOACTIVE AGENT, MEDICAL ARTICLES, AND METHODS

Since this Information Disclosure Statement is submitted after the receipt of an Office Action in the above-identified patent application, Applicants hereby authorize a charge of \$180.00 to Deposit Account No. 13-4895 to cover the fee required under 37 C.F.R. §§1.97(c) and 1.17(p). Please charge any additional fees or credit any overpayment to Deposit Account No. 13-4895.

The Examiner is invited to contact Applicants' Representatives at the below-listed telephone number, if they can be of any assistance during prosecution of the present application.

CERTIFICATE UNDER 37 C.F.R. 1.8:

The undersigned hereby certifies that this paper is being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: **Mail Stop Amendment**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 30 day of October, 2007.

By:

Name:

Ann M. Muetting
Ann M. Muetting

October 30, 2007

Date

Respectfully submitted
By
Muetting, Raasch & Gebhardt, P.A.
P.O. Box 581415
Minneapolis, MN 55458-1415
Phone: (612)305-1220
Facsimile: (612)305-1228

By *Ann M. Muetting*
Ann M. Muetting
Reg. No. 33,977
Direct Dial (612)305-1217